What question did this study set out to answer?

The aim is to explore the effectiveness of CRISPR-Cas12a gene editing on HBG1 and HBG2 promoters to treat β-thalassemia.

April 5, 2026New England Journal of Medicine12 citations

CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia

Q: What does this research mean for the field?

Treatment with reni-cel, a CRISPR-Cas12a gene editing therapy targeting HBG1 and HBG2 promoters, results in rapid neutrophil engraftment, increased fetal hemoglobin expression, and transfusion independence in patients with transfusion-dependent β-thalassemia. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

HFHaydar Frangoul RHRabi Hanna MWMark C. Walters

Key Points

The aim is to explore the effectiveness of CRISPR-Cas12a gene editing on HBG1 and HBG2 promoters to treat β-thalassemia.
Treatment with reni-cel administered to participants.
Evaluation of neutrophil engraftment post-treatment.
Measurement of fetal hemoglobin levels and transfusion dependency.
Rapid engraftment of neutrophils observed.
Significant increase in fetal hemoglobin expression noted.
Participants achieved transfusion independence after treatment.

Abstract

Treatment with reni-cel resulted in rapid neutrophil engraftment, an increase in fetal hemoglobin expression, and transfusion independence. These data support further investigation of Cas12a gene editing of the promoters of HBG1 and HBG2 in the treatment of transfusion-dependent β-thalassemia. (Funded by Editas Medicine; EdiThal ClinicalTrials.gov number, NCT05444894.).

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Frangoul et al. (2026) studied this question.

synapsesocial.com/papers/69d1fb20a79560c99a0a17cc https://doi.org/10.1056/nejmoa2501277

Ask AI

Helpful

Bookmark

View Full Paper

April 5, 2026New England Journal of Medicine12 citations

CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat β-Thalassemia

View Full Paper

HFHaydar Frangoul RHRabi Hanna MWMark C. Walters

Key Points

The aim is to explore the effectiveness of CRISPR-Cas12a gene editing on HBG1 and HBG2 promoters to treat β-thalassemia.
Treatment with reni-cel administered to participants.
Evaluation of neutrophil engraftment post-treatment.
Measurement of fetal hemoglobin levels and transfusion dependency.
Rapid engraftment of neutrophils observed.
Significant increase in fetal hemoglobin expression noted.
Participants achieved transfusion independence after treatment.

Abstract

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

Frangoul et al. (2026) studied this question.

synapsesocial.com/papers/69d1fb20a79560c99a0a17cc https://doi.org/10.1056/nejmoa2501277

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Ask AI

Helpful

Bookmark

View Full Paper